ANCA-associated vasculitides: Advances in pathophysiology and treatment

Netherlands Journal of Medicine

Volumn 68, Issue 2, 2010, Pages 62-67

  Erwig, L P ^a   Savage, C O S ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ANCA; Autoimmune disease; Churg Strauss vasculitis; Microscopic polyangiitis; Vasculitis; Wegeners granulomatosis

Indexed keywords

15 DEOXYSPERGUALINE; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ASTHMA; BLADDER CANCER; CANCER RISK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL ADHESION; CELL MIGRATION; CHURG STRAUSS SYNDROME; CLINICAL STUDY; CONTINUOUS INFUSION; COUGHING; CREATININE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSPNEA; EARLY DIAGNOSIS; ENDOTHELIUM CELL; EOSINOPHILIC CARDIOMYOPATHY; EPISCLERITIS; ERYTHROCYTE; FATIGUE; FEVER; FOREARM FRACTURE; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEARING IMPAIRMENT; HEART INFARCTION; HEMOPTYSIS; HOARSENESS; HUMAN; IMMUNIZATION; IN VITRO STUDY; INFECTION COMPLICATION; INFLAMMATORY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LUNG HEMORRHAGE; LYMPHOMA; MAINTENANCE THERAPY; MALAISE; MICROSCOPIC POLYANGIITIS; MONONEUROPATHY MULTIPLEX; NECROSIS; NEUTROPHIL; NONHUMAN; NONMELANOMA SKIN CANCER; NOSE SEPTUM; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN; PATHOPHYSIOLOGY; PLASMAPHERESIS; POLYARTERITIS NODOSA; POSTVIRAL FATIGUE SYNDROME; PREVENTION; PROPHYLAXIS; PURPURIC RASH; RELAPSE; REMISSION; RETINA VASCULITIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCLERITIS; SINUSITIS; SKIN CANCER; SKIN DEFECT; SOLID TUMOR; STAPHYLOCOCCUS AUREUS; THORAX RADIOGRAPHY; THROMBOCYTE; TREATMENT INDICATION; ULCER; UPPER RESPIRATORY TRACT INFECTION; URINE SEDIMENT; VALVULAR HEART DISEASE; VIRUS INFECTION; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID;

EID: 77949288726     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Watts RA, Scott DG, Jayne DR, et al. Renal vasculitis in Japan and the UK - are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant. 2008;23:3928-31.
2. Erwig LP, Rees AJ. Rapidly progressive glomerulonephritis. J Nephrol. 1999;12:111-9.
3. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776-84.
4. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J. 1982;285:606.
5. Van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-9.
6. Chen M, Kallenberg CEG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev. 2009. November. Epub.
7. Morgan MD, Harper L, Williams J, Savage C. Anti-neutrophil cytoplasmassociated glomerulonephritis. J Am Soc Nephrol. 2006;17:1224-34.
8. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology criteria for the classification of Churg Strauss syndrome. Arthritis Rheum. 1990;33:1094-1100.
9. Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol. 1993;33:4-9.
10. de Groot K, Adu D, Savage CO; EUVAS (European Vasculitis Study Group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;10:2018-27.
11. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80.
12. Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-8.
13. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461-9.
14. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract. 2006;102:100-7.
15. Little MA, Nightingale P, Verburgh CA, et al. Ann Rheum Dis. 2009;1. Epub ahead of print.
16. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44.
17. Popa ER, Stegeman CA, Kallenberg CG, Tervaert JW. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res. 2002;4(2):77-9.
18. Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004-10.
19. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43:1021-32.
20. Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 2009;60:3493-500.
21. Boomsma MM, Stegeman CA, Kramer AB, Karsijns M, Piers DA, Tervaert JW. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int. 2002;13(1):74-82.
22. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, van der Woude FJ; for the European Vasculitis Study Group. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65(4):1440-8.
23. Klein I, Vervoort G, Steenbergen E, Wetzels J. Progressive renal disease despite immunosuppressive therapy in a patient with Wegener's granulomatosis. Neth J Med. 2008;66(3):125-7.
24. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM. 1996;89(12):903-12.
25. Birck R, Warnatz K, Lorenz HM. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol. 2003;14(2):440-7.
26. Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant. 2005;20(6):1083-92.
27. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2009;60(7):2156-68.
28. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351-61.
29. Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med. 1989;149(11):2461-5.
30. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA. 1990;87(11):4115-9.
31. Nolan SL, Kalia N, Nash GB, Kamel D, Heeringa P, Savage CO. Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol. 2008;19(5):973-84.
32. Little MA, Savage CO. The role of the endothelium in systemic small vessel vasculitis. Clin Exp Rheumatol. 2008,26:S135-40.
33. Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophilendothelial cell interactions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol. 2005;77(1):33-43.
34. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955-63.
35. Pfister H, Ollert M, Fröhlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood. 2004;104(5):1411-8.
36. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood. 2005;106(6):2050-8.
37. Little MA, Smyth L, Salama AD, et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibodyassociated systemic vasculitis. Am J Pathol. 2009;174(4):1212-20.
38. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52-64.
39. Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71(7):646-54.
40. Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol. 2009;29(3):282-91.
41. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008;14(10):1088-96.